Momelotinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Momelotinib. Educational only — not medical advice.
Labeled uses
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
Source: FDA labeling via NIH DailyMed (set 4a672fd1…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.